OS Therapies Adds 2 Execs to Drive 3-Market Herlystic Launch

For biopharma teams tracking rare cancer commercialization, the leadership expansion at OS Therapies is a signal that an osteosarcoma immunotherapy may be closer to a regulatory decision than the current absence of efficacy disclosures suggests. The company is investing in commercial infrastructure across the U.S., U.K., and Europe before any approval, with a U.K. filing targeted for early Q4 2026 under Project Orbis. How quickly a new CCO can assemble a launch capability may determine whether a first regulatory win converts into early revenue.

OS Therapies, Inc. announced on October 1, 2026 that it has appointed Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer, according to a company press release. The dual appointment is less of a routine personnel update and more of a structural signal that the Maryland-based developer of gene-edited, Listeria-based cancer immunotherapies is moving decisively toward a potential first commercial launch. The CCO hire is specifically tied to Herlystic, also known as OST-HER2 or daznelimgene lisbac, an investigational immunotherapy intended to prevent or delay recurrence in patients with fully resected, pulmonary metastatic osteosarcoma. Although the therapy has not yet secured approval, the company is building a commercial organization across the United States, the United Kingdom, and Europe, with an initial U.S. launch planned if regulators clear the product.

“

announced on October 1, 2026 that it has appointed Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer, according to a company press release.

The strategic context matters. Osteosarcoma is a rare and aggressive bone cancer that predominantly affects adolescents and young adults. Patients who develop pulmonary metastases and undergo complete surgical resection still face a meaningful risk of recurrence, so a therapy that could delay or prevent that recurrence would address a substantial unmet need. Herlystic is positioned as an adjuvant-style immunotherapy in a post-resection setting, a design that may support expedited regulatory pathways. In this announcement, OS Therapies is not presenting new clinical data; rather, it is showing that it has enough confidence in the data and regulatory position to begin hiring for launch readiness. For a clinical-stage biotech, bringing in a CCO before approval is often a calculated bet on a near-term regulatory decision.

The regulatory strategy outlined in the release is unusually international. OS Therapies expects the United Kingdom's Medicines and Healthcare products Regulatory Agency to potentially be the first regulator to make a decision, ahead of the U.S. Food and Drug Administration and the European Medicines Agency. The company is pursuing a Conditional Marketing Authorization Application under Project Orbis through the Innovative Licensing and Access Pathway, with submission targeted for early in the fourth quarter of 2026. In parallel, OS Therapies has described plans for a U.S. Biologics License Application under the Accelerated Approval pathway and a Conditional Marketing Authorization Application in Europe. This multi-jurisdiction approach could allow the company to use a UK decision as a first commercialization opportunity while the FDA and EMA processes continue, but all timing and outcomes remain subject to regulatory review. The CCO's remit includes developing launch infrastructure, assessing patient and treatment-center needs, and preparing for market entry in each region, with the company stating that the United States would be the first launch market upon approval.

Kerry Clem's background is directly relevant to this challenge. The press release notes that he previously served as CEO of Solaxa and as Chief Commercial Officer at Acorda Therapeutics, with additional commercial leadership roles at Allos Therapeutics. Those roles suggest experience in specialty therapeutics and product launches, though the release does not provide specific launch metrics. Frank Knuettel II's appointment as CFO is announced in the headline, but the available source material does not detail his prior experience. In a pre-commercial company, the CFO role is often as much about capital formation as accounting; a new CFO may signal that OS Therapies is preparing for the financing required to support a commercial launch, including potential non-dilutive or equity capital raises.